{"title":"外用伊曲康唑纳米结构脂质载体凝胶治疗甲癣的研制","authors":"T. Kukreja, S. Saraf","doi":"10.52228/jrub.2023-35-2-2","DOIUrl":null,"url":null,"abstract":"\n Itraconazole is a triazole antifungal agent that is synthesised. Itraconazole has been manufactured into a variety of pharmacological formulations and administered by a variety of ways. Itraconazole pills are used to treat pulmonary fungal infections that can spread throughout the body. Because Itraconazole is not yet officially listed in any pharmacopoeia, only a few procedures for quality control and stability testing in pharmaceutical formulations have been published. The development of itraconazole-loaded nanostructured lipid carriers (ITZ-NLC). Itraconazole NLC have been successfully developed. Itraconazole topical NLC developed for the treatment of onychomycosis does not exist, according to my survey.The development and evaluation of stable itraconazole topical gel formulations proved successful. Itraconazole NLC was produced utilising the microemulsion method, indicating the viability of adopting this method as a continuous manufacturing tool for NLC formulation. Further, the ITZ- NLC was incorporated in the gelling agent and we evaluated it under specific parameters. \n","PeriodicalId":17214,"journal":{"name":"Journal of Ravishankar University (PART-B)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Formulation of Topical Itraconazole Nanostructured Lipid Carriers (Nlc) Gel for Onychomycosis\",\"authors\":\"T. Kukreja, S. Saraf\",\"doi\":\"10.52228/jrub.2023-35-2-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n Itraconazole is a triazole antifungal agent that is synthesised. Itraconazole has been manufactured into a variety of pharmacological formulations and administered by a variety of ways. Itraconazole pills are used to treat pulmonary fungal infections that can spread throughout the body. Because Itraconazole is not yet officially listed in any pharmacopoeia, only a few procedures for quality control and stability testing in pharmaceutical formulations have been published. The development of itraconazole-loaded nanostructured lipid carriers (ITZ-NLC). Itraconazole NLC have been successfully developed. Itraconazole topical NLC developed for the treatment of onychomycosis does not exist, according to my survey.The development and evaluation of stable itraconazole topical gel formulations proved successful. Itraconazole NLC was produced utilising the microemulsion method, indicating the viability of adopting this method as a continuous manufacturing tool for NLC formulation. Further, the ITZ- NLC was incorporated in the gelling agent and we evaluated it under specific parameters. \\n\",\"PeriodicalId\":17214,\"journal\":{\"name\":\"Journal of Ravishankar University (PART-B)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ravishankar University (PART-B)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52228/jrub.2023-35-2-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ravishankar University (PART-B)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52228/jrub.2023-35-2-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Formulation of Topical Itraconazole Nanostructured Lipid Carriers (Nlc) Gel for Onychomycosis
Itraconazole is a triazole antifungal agent that is synthesised. Itraconazole has been manufactured into a variety of pharmacological formulations and administered by a variety of ways. Itraconazole pills are used to treat pulmonary fungal infections that can spread throughout the body. Because Itraconazole is not yet officially listed in any pharmacopoeia, only a few procedures for quality control and stability testing in pharmaceutical formulations have been published. The development of itraconazole-loaded nanostructured lipid carriers (ITZ-NLC). Itraconazole NLC have been successfully developed. Itraconazole topical NLC developed for the treatment of onychomycosis does not exist, according to my survey.The development and evaluation of stable itraconazole topical gel formulations proved successful. Itraconazole NLC was produced utilising the microemulsion method, indicating the viability of adopting this method as a continuous manufacturing tool for NLC formulation. Further, the ITZ- NLC was incorporated in the gelling agent and we evaluated it under specific parameters.